Podsumowanie

Wśród objawów endokrynopatii pojawiają się objawy neurologiczne, w tym bóle głowy, zaburzenia rozwoju psychomotorycznego, parestezje, zaburzenia widzenia, miopatia, encefalopatia oraz różnego stopnia zaburzenia świadomości (w skrajnych przypadkach śpiączka). W diagnostyce różnicowej wymienionych zaburzeń neurologicznych należy zawsze uwzględniać endokrynopatie. Znajomość objawów neurologicznych towarzyszących zaburzeniom endokrynnym przyspiesza właściwą diagnozę i wdrożenie przyczynowego leczenia, a co za tym idzie – poprawia rokowanie. Wdrożenie odpowiedniego leczenia przyczynowego przywracającego równowagę hormonalną skutkuje często wycofaniem symptomów neurologicznych.

Abstract
Several hormones influence the development and function of the central nervous system as well as peripheral nerves. An excess or deficiency of particular hormonal substances may manifest as neurological symptoms, including headache, disturbances in psycho-motor development, paraesthesia, disturbed vision, myopathy, encephalopathy or loss of consciousness. Endocrinopathies should be considered in the differential diagnosis of the causes of those symptoms. Awareness of neurological symptoms of endocrine diseases may accelerate correct diagnosis and institution of appropriate treatment, and thus improve prognosis. Restoration of the hormonal balance often results in resolution of neurological symptoms.

Piśmiennictwo

1. Yu J. Endocrine disorders and the neurologic manifestations. Ann Pediatr Endocrinol Metab 2014;19:184-90.

2. Musumeci G, Castorina S, Castrogiovanni P, et al. A journey through the pituitary gland: development, structure and function, with emphasis on embryo-foetal and later development. Acta Histochem 2015;117:355-66.

3. Sasagawa Y, Tachibana O, Doai M, et al. Median nerve conduction studies and wrist magnetic resonance imaging in acromegalic patients with carpal tunnel syndrome. Pituitary 2015 Feb 8 [Epub ahead of print].

4. Baldys-Waligorska A, Krzentowska A, Golkowski F, et al. The prevalence of benign and malignant neoplasms in acromegalic patients. Endokrynol Pol 2010;61:29-34.

5. Bolanowski M, Ruchala M, Zgliczynski W, et al. Acromegaly – a novel view of the patient. Polish proposals for diagnostic and therapeutic procedures in the light of recent reports. Endokrynol Pol 2014;65:326-31.

6. Bolanowski M, Zatonska K, Kaluzny M, et al. A follow-up of 130 patients with acromegaly in a single centre. Neuro Endocrinol Lett 2006;27:828-32.

7. Tseng CH, Liao CC, Kuo CM, et al. Medical and non-medical correlates of carpal tunnel syndrome in a Taiwan cohort of one million. Eur J Neurol 2012;19:91-7.

8. Tagliafico A, Resmini E, Ferone D, et al. Musculoskeletal complications of acromegaly: what radiologists should know about early manifestations. Radiol Med 2011;116:781-92.

9. Pearce JM. On the Origins of Pituitary Apoplexy. Eur Neurol 2015;74:18-21.

10. Roerink SH, van Lindert EJ, van de Ven AC. Spontaneous remission of acromegaly and Cushing’s disease following pituitary apoplexy: Two case reports. Neth J Med 2015;73:242-6.

11. Styk A, Zielinski G. Pituitary apoplexy – not always correctly recognized life-threatening entity. Pol Merkur Lekarski 2015;38:340-3.

12. Watson JC, Dyck PJ. Peripheral Neuropathy: A Practical Approach to Diagnosis and Symptom Management. Mayo Clin Proc 2015;90:940-51.

13. Merashli M, Chowdhury TA, Jawad AS. Musculoskeletal manifestations of diabetes mellitus. QJM 2015 May 28. pii: hcv106. [Epub ahead of print].

14. Mulder L, Onur O, Kleis L, et al. Atypical neurologic presentations of new onset type 1 diabetes mellitus in pediatric age group: a report of five unusual cases and review of the literature. J Pediatr Endocrinol Metab 2014;27:749-56.

15. Villar J, Finol HJ, Torres SH, et al. Myopathy in patients with Hashimoto’s disease. Invest Clin 2015;56:33-46.

16. Tsang CC, Hui WS, Lo KM, et al. Anti-thyroid drugs-related myopathy: is carbimazole the real culprit? Int J Endocrinol Metab 2015 Jan;13(1):e17570.

17. De Groot LJ, Bartalena L. Thyroid Storm. In: De Groot LJ, Beck-Peccoz P, Chrousos G, et al. (editors). Source Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc;2000-2015 Apr 12.

18. Ruchala M, Szczepanek E, Tamborska-Zedlewska M, et al. Congenital hypothyroidism simulating acromegaly – a diagnostic pitfall. Neuro Endocrinol Lett 2009;30:322-6.

19. Shi X, Sun Y, Qiang R. Undiagnosed congenital hypothyroidism in a newborn treated with dopamine infusion. J Trop Pediatr 2015;61:215-7.

20. Jbara Y, Bricker D. Rhabdomyolysis in the setting of induced hypothyroidism and statin therapy: a case report. Eur Thyroid J 2015;4:62-4.

21. Shiri R. Hypothyroidism and carpal tunnel syndrome: a meta-analysis. Muscle Nerve 2014;50:879-83.

22. Ittermann T, Volzke H, Baumeister SE, et al. Diagnosed thyroid disorders are associated with depression and anxiety. Soc Psychiatry Psychiatr Epidemiol 2015 Mar 17. [Epub ahead of print].

23. Wiersinga WM. Myxedema and Coma (Severe Hypothyroidism). In: De Groot LJ, Beck-Peccoz P, Chrousos G, et al. (editors). Source Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.;2000-2012 Jul 21.

24. Pyzik A, Grywalska E, Matyjaszek-Matuszek B, et al. Immune disorders in Hashimoto’s thyroiditis: what do we know so far? J Immunol Res 2015;979167.

25. Ruchala M, Szczepanek E, Skiba A, et al. Graves’ hyperthyroidism following primary hypothyroidism due to Hashimoto’s thyroiditis in a case of thyroid hemiagenesis: case report. Neuro Endocrinol Lett 2008;29:55-8.

26. Ruchala M, Kosowicz J, Baumann-Antczak A, et al. The prevalence of autoantibodies to: myosin, troponin, tropomyosin and myoglobin in patients with circulating triiodothyronine and thyroxine autoantibodies (THAA). Neuro Endocrinol Lett 2007;28:259-66.

27. Tagoe CE. Rheumatic symptoms in autoimmune thyroiditis. Curr Rheumatol Rep 2015;17:5.

28. Robles-Cedeno R, Gich J, Genis Batlle D, et al. Rapidly progressive dementia with false-positive PCR Tropheryma whipplei in CSF. A case of Hashimoto’s encephalopathy. J Neurol Sci 2015;355:213-5.

29. Bono G, Fancellu R, Blandini F, et al. Cognitive and affective status in mild hypothyroidism and interactions with L-thyroxine treatment. Acta Neurol Scand 2004;110:59-66.

30. Czarnywojtek A, Zgorzalewicz-Stachowiak M, Stangierski A, et al. Thyroid associated orbitopathy – medication, radioiodine or operation? Przegl Lek 2012;69:1140-3.

31. Pivonello R, Simeoli C, De Martino MC, et al. Neuropsychiatric disorders in Cushing’s syndrome. Front Neurosci 2015 Apr 20;9:129. doi: 10.3389/fnins.2015.00129. eCollection 2015.9 129.

32. Raff H. Cushing syndrome: update on testing. Endocrinol Metab Clin North Am 2015;44(1):43-50. doi: 10.1016/j.ecl.2014.10.005.

33. Johannsson G, Falorni A, Skrtic S, et al. Adrenal insufficiency: review of clinical outcomes with current glucocorticoid replacement therapy. Clin Endocrinol (Oxf) 2015;82:2-11.

34. Abdelkefi M, Abdallah M, Larbi T, et al. Pseudo myopathy revealing primary hyperparathyroidism: a case report. Tunis Med 2014;92:766.

35. Cosci F, Fava GA, Sonino N. Mood and anxiety disorders as early manifestations of medical illness: a systematic review. Psychother Psychosom 2015;84:22-9.

36. Policepatil SM, Caplan RH, Dolan M. Hypocalcemic myopathy secondary to hypoparathyroidism. WMJ 2012;111:173-5.

Do góry